PTC Therapeutics (PTCT) reported Q3 EPS of ($1.53), $0.22 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $217.1 million versus the consensus estimate of $178.9 million.
PTC Therapeutics (PTCT) reported Q3 EPS of ($1.53), $0.22 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $217.1 million versus the consensus estimate of $178.9 million.